Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 27
2017 4
2019 1
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Results by year

Filters applied: . Clear all
Page 1
With one eye on the future.
Caldas C, Rescigno M, Turajlic S, Madabhushi A, Zhang Z, Lito P, Brown CE, Pantel K, Haanen J, Duma N. Caldas C, et al. Cancer Cell. 2022 Mar 14;40(3):221-225. doi: 10.1016/j.ccell.2022.02.019. Cancer Cell. 2022. PMID: 35290781 Free article.
6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.
Earl HM, Hiller L, Vallier AL, Loi S, McAdam K, Hughes-Davies L, Harnett AN, Ah-See ML, Simcock R, Rea D, Raj S, Woodings P, Harries M, Howe D, Raynes K, Higgins HB, Wilcox M, Plummer C, Mansi J, Gounaris I, Mahler-Araujo B, Provenzano E, Chhabra A, Abraham JE, Caldas C, Hall PS, McCabe C, Hulme C, Miles D, Wardley AM, Cameron DA, Dunn JA; PERSEPHONE Steering Committee and Trial Investigators. Earl HM, et al. Lancet. 2019 Jun 29;393(10191):2599-2612. doi: 10.1016/S0140-6736(19)30650-6. Epub 2019 Jun 6. Lancet. 2019. PMID: 31178152 Free PMC article. Clinical Trial.
Interrogating open issues in cancer precision medicine with patient-derived xenografts.
Byrne AT, Alférez DG, Amant F, Annibali D, Arribas J, Biankin AV, Bruna A, Budinská E, Caldas C, Chang DK, Clarke RB, Clevers H, Coukos G, Dangles-Marie V, Eckhardt SG, Gonzalez-Suarez E, Hermans E, Hidalgo M, Jarzabek MA, de Jong S, Jonkers J, Kemper K, Lanfrancone L, Mælandsmo GM, Marangoni E, Marine JC, Medico E, Norum JH, Palmer HG, Peeper DS, Pelicci PG, Piris-Gimenez A, Roman-Roman S, Rueda OM, Seoane J, Serra V, Soucek L, Vanhecke D, Villanueva A, Vinolo E, Bertotti A, Trusolino L. Byrne AT, et al. Nat Rev Cancer. 2017 Apr;17(4):254-268. doi: 10.1038/nrc.2016.140. Epub 2017 Jan 20. Nat Rev Cancer. 2017. PMID: 28104906 Free article. Review.
Prognostic Value of MammaPrint® in Invasive Lobular Breast Cancer.
Beumer IJ, Persoon M, Witteveen A, Dreezen C, Chin SF, Sammut SJ, Snel M, Caldas C, Linn S, van 't Veer LJ, Bernards R, Glas AM. Beumer IJ, et al. Biomark Insights. 2016 Dec 11;11:139-146. doi: 10.4137/BMI.S38435. eCollection 2016. Biomark Insights. 2016. PMID: 27980389 Free PMC article.
Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration.
Smid M, Rodríguez-González FG, Sieuwerts AM, Salgado R, Prager-Van der Smissen WJ, Vlugt-Daane MV, van Galen A, Nik-Zainal S, Staaf J, Brinkman AB, van de Vijver MJ, Richardson AL, Fatima A, Berentsen K, Butler A, Martin S, Davies HR, Debets R, Gelder ME, van Deurzen CH, MacGrogan G, Van den Eynden GG, Purdie C, Thompson AM, Caldas C, Span PN, Simpson PT, Lakhani SR, Van Laere S, Desmedt C, Ringnér M, Tommasi S, Eyford J, Broeks A, Vincent-Salomon A, Futreal PA, Knappskog S, King T, Thomas G, Viari A, Langerød A, Børresen-Dale AL, Birney E, Stunnenberg HG, Stratton M, Foekens JA, Martens JW. Smid M, et al. Nat Commun. 2016 Sep 26;7:12910. doi: 10.1038/ncomms12910. Nat Commun. 2016. PMID: 27666519 Free PMC article.
30 results